LIPPS BINIE V has a total of 17 patent applications. Its first patent ever was published in 1995. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are PROGEN CO LTD, CELLERANT THERAPEUTICS INC and HER MAJESTY THE QUEEN IN RIGHT OF CANADA AS REPRESENTED BY THE MINI OF HEALTH.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 7 | |
#2 | WIPO (World Intellectual Property Organization) | 5 | |
#3 | Australia | 2 | |
#4 | EPO (European Patent Office) | 2 | |
#5 | Canada | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Peptides | |
#3 | Therapeutic chemical compounds | |
#4 | Microorganisms | |
#5 | Analysing materials | |
#6 | Specific use of cosmetics |
# | Name | Total Patents |
---|---|---|
#1 | Lipps Binie V | 17 |
#2 | Lipps Frederick W | 11 |
Publication | Filing date | Title |
---|---|---|
US2008081788A1 | Diagnosis and treatment for immunoglobulin E (IgE) implicated disorders | |
US2006142190A1 | Synthetic peptide, inhibitor to DNA viruses | |
WO03060471A2 | Diagnosis and treatment for immunoglobulin e (ige) implicated disorders | |
US7183258B2 | Two synthetic peptides for treatment and prevention of cancers | |
US7129334B2 | Synthetic peptide and uses for same | |
WO0203922A2 | Synthetic peptide for neurological disorders | |
CA2189357A1 | Beta taipoxin as a cell growth factor and method |